Docetaxel, Capecitabine and Carboplatin in Metastatic Esophagogastric Cancer: A Phase II Study

Evans, Devon; Miner, Thomas J.; Iannitti, David A.; Akerman, Paul A.; Cruff, Dennis; Maia-Acuna, Christine; Harrington, David; Habr, Fadlallah; Chauhan, B.; Berkenblit, Anna; Stuart, Keith; Sears, Dina; Kennedy, T. A.; Safran, Howard

doi:10.1080/07357900701358025

Cited by 10 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30,[53][54][55][56][57] Evans et al have further modified the DCF regimen by substituting cisplatin with carboplatin to reduce neurotoxicity, while increasing the convenience of the regimen by substi-tuting capecitabine for 5-FU. 58 The docetaxel, carboplatin, and capecitabine regimen was found to be well tolerated in this phase 2 study, with grade 3 neutropenia and grade 3 diarrhea, nausea/vomiting, and dehydration being the most notable toxicities. Responses were observed in 48% of patients, with complete responses noted in 3 patients; the median OS was 8 months (95% CI, 5.5 months-13 months) and the 1-year survival rate was 36%.…”

mentioning

confidence: 99%

Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction

Ajani

2008

Cancer

View full text Add to dashboard Cite

Advanced gastroesophageal cancer patients are often treated with systemic combination chemotherapy. The V-325 study demonstrated that adding docetaxel (D) to a frequently used regimen of cisplatin and 5-fluorouracil (CF) provided benefits with regard to overall survival, response rate, time-to-disease progression, clinical benefit, and health-related quality of life. Although the DCF regimen provides these advantages, it is accompanied by an increase in toxicity compared with the doublet regimen. The toxicity profile of DCF is acceptable only with appropriately selected patients and comprehensive toxicity management strategies. The objective of the current review was to identify trials that investigated modifications to the original DCF regimen to improve its toxicity profile and summarize response rate and toxicities. An attempt was also made to summarize ongoing modifications of the DCF regimen. MEDLINE, major meeting proceedings, and the government clinical trials website were searched until 2007. The modified DCF regimens appear to improve the toxicity profile when compared with the original DCF regimen. The docetaxel-based triplet combinations appear to have a higher response rate than the doublet combinations. Many institutions and cooperative groups continue to study docetaxel-based modifications of the DCF regimen to treat patients with gastroesophageal carcinoma. However, although modified DCF reduces the frequency of severe toxicities previously reported with DCF, considerably more advances are needed to improve the safety, survival, and convenience of patients with advanced gastroesophageal cancer.

show abstract

mentioning

confidence: 99%

Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction

Ajani

2008

Cancer

View full text Add to dashboard Cite

show abstract

“…Evans et al [19] Tsai et al [20] used carboplatin (area under the ROC curve AUC = 2) on day 1 and 8, docetaxel Lee et al [21] used two cycles of XP induction chemotherapy, consisting of capecitabine 1000 mg/m The median time of progression was 7.8 mo (95% CI, 6.0-9.5 mo) and the median overall survival was 12.0 mo (95% CI, 9.0-15.0 mo). Evans et al [22] used a regimen comprised of docetaxel 40 mg/m 2 , on day 1 and 8, carboplatin (AUC = 2) on day 1 and 8, and capecitabine 2000 mg/m 2 , on days 1-10 in a 21-day cycle. The median survival was 8.0 mo (95% CI, 5.5-13.0 mo), and the 1-year survival rate was 36.0%.…”

Section: Qin Tj Et Al Oxaliplatin Plus Capecitabine In Metastatic Esccmentioning

confidence: 99%

Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer

Qin¹,

An²,

Zhao³

et al. 2009

WJG

View full text Add to dashboard Cite

AIM:To investigate the efficacy and side effects of the combined therapy of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer (ESCC) and the survival of the patients. METHODS:Sixty-four patients (median age of 63 years) with histological or cytological confirmation of ESCC received oxaliplatin 120 mg/m 2 intravenously on day 1 and capecitabine 1000 mg/m 2 orally twice daily on days 1 to 14 in a 21-d treatment cycle as palliative chemotherapy. Each patient received at least two cycles of treatment. The efficacy, side effects and patient survival were evaluated. RESULTS:The partial response (PR) rate was 43.8% (28/64). Stable disease (SD) rate was 47.9% (26/64), and disease progression rate was 15.6% (10/64). The clinical benefit rate (PR + SD) was 84.4%. The main toxicities were leukopenia (50.0%), nausea and vomiting (51.6%), diarrhea (50.0%), stomatitis (39.1%), polyneuropathy (37.5%) and hand-foot syndrome (37.5%). No grade 4 event in the entire cohort was found. The median progression-free survival was 4 mo, median overall survival was 10 mo (95% CI: 8.3-11.7 mo), and the 1-and 2-year survival rates were 38.1% and 8.2%, respectively. High Karnofsky index, single metastatic lesion and response to the regimen indicated respectively good prognosis. CONCLUSION:Oxaliplatin plus capecitabine regimen is effective and tolerable in metastatic ESCC patients. The regimen has improved the survival moderately and merits further studies.

show abstract

“…In this context, a phase II study with a modified DCF regimen (including weekly docetaxel, carboplatin plus capecitabine) was tested [12]. The response rates and 1-year survival data were comparable to similar more complex regimens, and the combination was well tolerated [12]. Furthermore, oxaliplatin in combination with capecitabine seems to be as effective as 5-FU plus cisplatin in patients with previously untreated esophagogastric cancer [10].…”

Section: Introductionmentioning

confidence: 99%

“…Capecitabine, an orally administered prodrug of 5-FU, has been demonstrated to be non-inferior to 5-FU in the treatment of advanced esophagogastric cancer in two large phase III trials [10,11]. In this context, a phase II study with a modified DCF regimen (including weekly docetaxel, carboplatin plus capecitabine) was tested [12]. The response rates and 1-year survival data were comparable to similar more complex regimens, and the combination was well tolerated [12].…”

Section: Introductionmentioning

confidence: 99%

Docetaxel plus Oxaliplatin in Combination with Capecitabine as First-Line Treatment for Advanced Gastric Cancer

Amarantidis¹,

Xenidis²,

Chelis³

et al. 2011

Oncology

View full text Add to dashboard Cite

Objective: In the present phase II study, we evaluated the efficacy and safety of a docetaxel-oxaliplatin-capecitabine combination as a first-line treatment in patients with advanced gastric cancer. Patients and Methods: A total of 27 patients (18 males) with histologically confirmed inoperable gastric adenocarcinoma were recruited. Docetaxel was given (50 mg/m² i.v.) on day 1 followed by oxaliplatin (75 mg/m² i.v.) also on day 1. Capecitabine (2,750 mg/m²) was given orally as two daily divided doses from days 1 to 7. Cycles were repeated every 2 weeks. All patients had measurable disease and 18 of them had a performance status (WHO) of 0. Results: A total of 240 treatment cycles were administered. All patients were evaluable for toxicity. Four patients who discontinued treatment early (having received only 3 chemotherapy cycles) were included as non-responders in an intention-to-treat response analysis. Complete response, partial response, stable disease and progressive disease were observed in 4 (15%), 12 (44%), 3 (11%) and 8 (30%) patients, respectively. The observed response rate was 59%, and the disease control rate (complete response + partial response + stable disease) was 70%. At the time of analysis, 6 patients were still alive and the median survival was 18.0 months. The most common grade III/IV toxicities observed were neutropenia (5%), diarrhea (2%), palmar-plantar erythrodysesthesia (2%) and neurotoxicity (1%). All other toxicities were mostly of grade I/II and easily manageable. Conclusion: The combination of docetaxel, oxaliplatin and capecitabine in the described mode of administration represents a relatively active and well-tolerated regimen in patients with advanced gastric cancer and warrants further evaluation.

show abstract

Docetaxel, Capecitabine and Carboplatin in Metastatic Esophagogastric Cancer: A Phase II Study

Abstract: Weekly docetaxel and carboplatin with capecitabine was an easily administered outpatient regimen. The response rate and 1-year survival were similar to more complex regimens. Future trials may investigate the substitution of carboplatin with more active agents.

Cited by 10 publications

References 19 publications

Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction

Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction

Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer

Docetaxel plus Oxaliplatin in Combination with Capecitabine as First-Line Treatment for Advanced Gastric Cancer

Contact Info

Product

Resources

About